R'Biz
RSS Feed
 
A A A
New Products & Services

In Brief …

Quick clips from around the Richmond business scene



Related Articles

More R'Biz »

James A. Bacon
Richmond.com
Saturday, September 06, 2008

Bostwick Therapeutics, a Seattle-based division of Bostwick Laboratories, has received clearance from the U.S. Food and Drug Administration to initiate a clinical trial examining the potential of a novel combination of freezing tumors and injecting "virgin" dendritic cells into them as a treatment for certain types of prostate cancer. Bostwick Laboratories is a market leader in urologic pathology. More.  

Printer Friendly Version  Email Article to a Friend  RSS Feeds

Tags: Life sciences 

0 comments.

Name: *
E-Mail:
URL:
Comment: *
What is 2 + 2? *
To help protect against spam, please answer the above question

  

Disclaimer: Richmond.com reserves the right to edit and/or publish your contributions via e-mail, story comments, etc. Inappropriate comments will be subject to immediate removal without notice.